Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
How SARS-CoV-2 binds to human cells
Scientists are racing to learn the secrets of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), which is the cause of the pandemic disease COVID-19. The first step in viral entry is the binding of the viral trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2). Yan et al. present the structure of human ACE2 in complex with a membrane protein that it chaperones, B0AT1. In the context of this complex, ACE2 is a dimer. A further structure shows how the receptor binding domain of SARS-CoV-2 interacts with ACE2 and suggests that it is possible that two trimeric spike proteins bind to an ACE2 dimer. The structures provide a basis for the development of therapeutics targeting this crucial interaction.
Science, this issue p. 1444
Abstract
Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for severe acute respiratory syndrome–coronavirus (SARS-CoV) and the new coronavirus (SARS-CoV-2) that is causing the serious coronavirus disease 2019 (COVID-19) epidemic. Here, we present cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein (S protein) of SARS-CoV-2, both at an overall resolution of 2.9 angstroms, with a local resolution of 3.5 angstroms at the ACE2-RBD interface. The ACE2-B0AT1 complex is assembled as a dimer of heterodimers, with the collectrin-like domain of ACE2 mediating homodimerization. The RBD is recognized by the extracellular peptidase domain of ACE2 mainly through polar residues. These findings provide important insights into the molecular basis for coronavirus recognition and infection.
Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is a positive-strand RNA virus that causes severe respiratory syndrome in humans. The resulting outbreak of coronavirus disease 2019 (COVID-19) has emerged as a severe epidemic, claiming more than 2000 lives worldwide between December 2019 and February 2020 (1, 2). The genome of SARS-CoV-2 shares about 80% identity with that of SARS-CoV and is about 96% identical to the bat coronavirus BatCoV RaTG13 (2).
In the case of SARS-CoV, the spike glycoprotein (S protein) on the virion surface mediates receptor recognition and membrane fusion (3, 4). During viral infection, the trimeric S protein is cleaved into S1 and S2 subunits and S1 subunits are released in the transition to the postfusion conformation (4–7). S1 contains the receptor binding domain (RBD), which directly binds to the peptidase domain (PD) of angiotensin-converting enzyme 2 (ACE2) (8), whereas S2 is responsible for membrane fusion. When S1 binds to the host receptor ACE2, another cleavage site on S2 is exposed and is cleaved by host proteases, a process that is critical for viral infection (5, 9, 10). The S protein of SARS-CoV-2 may also exploit ACE2 for host infection (2, 11–13). A recent publication reported the structure of the S protein of SARS-CoV-2 and showed that the ectodomain of the SARS-CoV-2 S protein binds to the PD of ACE2 with a dissociation constant (Kd) of ~15 nM (14).
Although ACE2 is hijacked by some coronaviruses, its primary physiological role is in the maturation of angiotensin (Ang), a peptide hormone that controls vasoconstriction and blood pressure. ACE2 is a type I membrane protein expressed in lungs, heart, kidneys, and intestine (15–17). Decreased expression of ACE2 is associated with cardiovascular diseases (18–20). Full-length ACE2 consists of an N-terminal PD and a C-terminal collectrin-like domain (CLD) that ends with a single transmembrane helix and a ~40-residue intracellular segment (15, 21). The PD of ACE2 cleaves Ang I to produce Ang-(1-9), which is then processed by other enzymes to become Ang-(1-7). ACE2 can also directly process Ang II to give Ang-(1-7) (15, 22).
Structures of the claw-like ACE2-PD alone and in complex with the RBD or the S protein of SARS-CoV have revealed the molecular details of the interaction between the RBD of the S protein and PD of ACE2 (7, 8, 23, 24). Structural information on ACE2 is limited to the PD domain. The single transmembrane (TM) helix of ACE2 makes it challenging to determine the structure of the full-length protein.
ACE2 also functions as the chaperone for membrane trafficking of the amino acid transporter B0AT1, also known as SLC6A19 (25), which mediates uptake of neutral amino acids into intestinal cells in a sodium-dependent manner. Mutations in B0AT1 may cause Hartnup disorder, an inherited disease with symptoms such as pellagra, cerebellar ataxia, and psychosis (26–28). Structures have been determined for the SLC6 family members dDAT (Drosophila dopamine transporter) and human SERT (serotonin transporter, SLC6A4) (29, 30). It is unclear how ACE2 interacts with B0AT1. The membrane trafficking mechanism for ACE2 and B0AT1 is similar to that of the LAT1-4F2hc complex, a large neutral–amino acid transporter complex that requires 4F2hc for its plasma membrane localization (31). Our structure of LAT1-4F2hc shows that the cargo LAT1 and chaperone 4F2hc interact through both extracellular and transmembrane domains (32). We reasoned that the structure of full-length ACE2 may be revealed in the presence of B0AT1.
Here, we report cryo–electron microscopy (cryo-EM) structures of the full-length human ACE2-B0AT1 complex at an overall resolution of 2.9 Å and a complex between the RBD of SARS-CoV-2 and the ACE2-B0AT1 complex, also with an overall resolution of 2.9 Å and with 3.5-Å local resolution at the ACE2-RBD interface. The ACE2-B0AT1 complex exists as a dimer of heterodimers. Structural alignment of the RBD-ACE2-B0AT1 ternary complex with the S protein of SARS-CoV-2 suggests that two S protein trimers can simultaneously bind to an ACE2 homodimer.
Structural determination of the ACE2-B0AT1 complex
Full-length human ACE2 and B0AT1, with Strep and FLAG tags on their respective N termini, were coexpressed in human embryonic kidney (HEK) 293F cells and purified through tandem affinity resin and size exclusion chromatography. The complex was eluted in a single monodisperse peak, indicating high homogeneity (Fig. 1A). Details of cryo-sample preparation, data acquisition, and structural determination are given in the materials and methods section of the supplementary materials. A three-dimensional (3D) reconstruction was obtained at an overall resolution of 2.9 Å from 418,140 selected particles. This immediately revealed the dimer of heterodimers’ architecture (Fig. 1B). After applying focused refinement and C2 symmetry expansion, the resolution of the extracellular domains improved to 2.7 Å, whereas the TM domain remained at 2.9-Å resolution (Fig. 1B, figs. S1 to S3, and table S1).
Fig. 1 Overall structure of the ACE2-B0AT1 complex.
(A) Representative size exclusion chromatography purification profile of full-length human ACE2 in complex with B0AT1. UV, ultraviolet; mAU, milli–absorbance units; MWM, molecular weight marker. (B) Cryo-EM map of the ACE2-B0AT1 complex. The map is generated by merging the focused refined maps shown in fig. S2. Protomer A of ACE2 (cyan), protomer B of ACE2 (blue), protomer A of B0AT1 (pink) and protomer B of B0AT1 (gray) are shown. (C) Cartoon representation of the atomic model of the ACE2-B0AT1 complex. The glycosylation moieties are shown as sticks. The complex is colored by subunits, with the PD and CLD in one ACE2 protomer colored cyan and blue, respectively. (D) An open conformation of the ACE2-B0AT1 complex. The two PDs, which contact each other in the closed conformation, are separated in the open conformation.
The high resolution supported reliable model building. For ACE2, side chains could be assigned to residues 19 to 768, which contain the PD (residues 19 to 615) and the CLD (residues 616 to 768), which consists of a small extracellular domain, a long linker, and the single TM helix (Fig. 1C). Between the PD and TM helix is a ferredoxin-like fold domain; we refer to this as the neck domain (residues 616 to 726) (Fig. 1C and fig. S4). Homodimerization is entirely mediated by ACE2, which is sandwiched by B0AT1. Both the PD and neck domains contribute to dimerization, whereas each B0AT1 interacts with the neck and TM helix in the adjacent ACE2 (Fig. 1C). The extracellular region is highly glycosylated, with seven and five glycosylation sites on each ACE2 and B0AT1 monomer, respectively.
During classification, another subset with 143,857 particles was processed to an overall resolution of 4.5 Å. Whereas the neck domain still dimerizes, the PDs are separated from each other in this reconstruction (Fig. 1D and fig. S1, H to K). We therefore define the two classes as the open and closed conformations. Structural comparison shows that the conformational changes are achieved through rotation of the PD domains, with the rest of the complex left nearly unchanged (movie S1).
Homodimer interface of ACE2
Dimerization of ACE2 is mainly mediated by the neck domain, with the PD contributing a minor interface (Fig. 2A). The two ACE2 protomers are hereafter referred to as A and B, with residues in protomer B followed by a prime symbol. Extensive polar interactions are mapped to the interface between the second (residues 636 to 658) and fourth (residues 708 to 717) helices of the neck domain (Fig. 2B). Arg652 and Arg710 in ACE2-A form cation-π interactions with Tyr641′ and Tyr633′ in ACE2-B. Meanwhile, Arg652 and Arg710 are respectively hydrogen-bonded (H-bonded) to Asn638′ and Glu639′, which also interact with Gln653, as does Asn636′. Ser709 and Asp713 from ACE2-A are H-bonded to Arg716′. This extensive network of polar interactions indicates stable dimer formation.
Fig. 2 Dimerization interface of ACE2.
(A) ACE2 dimerizes through two interfaces, the PD and the neck domain. The regions enclosed by the cyan and red dashed lines are illustrated in detail in (B) and (C), respectively. (B) The primary dimeric interface is through the neck domain in ACE2. Polar interactions are represented by red dashed lines. (C) A weaker interface between PDs of ACE2. The only interaction is between Gln139 and Gln175′, which are highlighted as spheres. The polar residues that may contribute to the stabilization of Gln139 are shown as sticks. (D) The PDs no longer contact each other in the open state. Single-letter abbreviations for the amino acid residues used in the figures are as follows: C, Cys; D, Asp; E, Glu; F, Phe; H, His; K, Lys; L, Leu; M, Met; N, Asn; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; and Y, Tyr.
The PD dimer interface appears much weaker, with only one pair of interactions between Gln139 and Gln175′ (Fig. 2C). Gln139 is in a loop that is stabilized by a disulfide bond between Cys133 and Cys141 as well as multiple intraloop polar interactions (Fig. 2C). The weak interaction is consistent with the ability to transition to the open conformation, in which the interface between the neck domains remains the same while the PDs are separated from each other by ~25 Å (Fig. 2D and movie S1).
Overall structure of the RBD-ACE2-B0AT1 complex
To gain insight into the interaction between ACE2 and SARS-CoV-2, we purchased 0.2 mg of recombinantly expressed and purified RBD-mFc of SARS-CoV-2 (for simplicity, hereafter referred to as RBD; mFc, mouse Fc tag) from Sino Biological Inc., mixed it with our purified ACE2-B0AT1 complex at a stoichiometric ratio of ~1.1 to 1, and proceeded with cryo-grid preparation and imaging. Finally, a 3D EM reconstruction of the ternary complex was obtained.
In contrast to the ACE2-B0AT1 complex—which has two conformations, open and closed—only the closed state of ACE2 was observed in the dataset for the RBD-ACE2-B0AT1 ternary complex. The structure of the ternary complex was determined to an overall resolution of 2.9 Å from 527,017 selected particles. However, the resolution for the ACE2-B0AT1 complex was substantially higher than that for the RBDs, which are at the periphery of the complex (Fig. 3A). To improve the local resolution, focused refinement was applied; this allowed us to reach a resolution of 3.5 Å for the RBD, supporting reliable modeling and analysis of the interface (Fig. 3, figs. S5 to S7, and table S1).
Fig. 3 Overall structure of the RBD-ACE2-B0AT1 complex.
(A) Cryo-EM map of the RBD-ACE2-B0AT1 complex. The overall reconstruction of the ternary complex at 2.9 Å is shown on the left. The inset shows the focused refined map of RBD. The color scheme is the same as that in Fig. 1B, with the addition of red and gold, which represent RBD protomers. (B) Overall structure of the RBD-ACE2-B0AT1 complex. The color scheme is the same as that in Fig. 1C. The glycosylation moieties are shown as sticks.
Interface between the RBD and ACE2
As expected, each PD accommodates one RBD (Fig. 3B). The overall interface is similar to that between SARS-CoV and ACE2 (7, 8), mediated mainly through polar interactions (Fig. 4A). An extended loop region of the RBD spans the arch-shaped α1 helix of the ACE2-PD like a bridge. The α2 helix and a loop that connects the β3 and β4 antiparallel strands, referred to as loop 3-4, of the PD also make limited contributions to the coordination of the RBD.
Fig. 4 Interactions between SARS-CoV-2-RBD and ACE2.
(A) The PD of ACE2 mainly engages the α1 helix in the recognition of the RBD. The α2 helix and the linker between β3 and β4 also contribute to the interaction. Only one RBD-ACE2 is shown. (B to D) Detailed analysis of the interface between SARS-CoV-2-RBD and ACE2. Polar interactions are indicated by red dashed lines. NAG, N-acetylglucosamine.
The contact can be divided into three clusters. The two ends of the bridge interact with the N and C termini of the α1 helix as well as small areas on the α2 helix and loop 3-4. The middle segment of α1 reinforces the interaction by engaging two polar residues (Fig. 4A). At the N terminus of α1, Gln498, Thr500, and Asn501 of the RBD form a network of H-bonds with Tyr41, Gln42, Lys353, and Arg357 from ACE2 (Fig. 4B). In the middle of the bridge, Lys417 and Tyr453 of the RBD interact with Asp30 and His34 of ACE2, respectively (Fig. 4C). At the C terminus of α1, Gln474 of the RBD is H-bonded to Gln24 of ACE2, whereas Phe486 of the RBD interacts with Met82 of ACE2 through van der Waals forces (Fig. 4D).
Comparing the SARS-CoV-2 and SARS-CoV interfaces with ACE2
Superimposition of the RBD in the complex of SARS-CoV (SARS-CoV-RBD) and ACE2-PD [Protein Data Bank (PDB) 2AJF] with the RBD in our ternary complex shows that the SARS-CoV-2 RBD (SARS-CoV-2-RBD) is similar to SARS-CoV-RBD with a root mean square deviation (RMSD) of 0.68 Å over 139 pairs of Cα atoms (Fig. 5A) (8). Despite the overall similarity, a number of sequence variations and conformational deviations are found in their respective interfaces with ACE2 (Fig. 5 and fig. S8). At the N terminus of α1, the variations Arg426→Asn439, Tyr484→Gln498, and Thr487→Asn501 at equivalent positions are observed between SARS-CoV-RBD and SARS-CoV-2-RBD (Fig. 5B). More variations are observed in the middle of the bridge. The most prominent alteration is the substitution of Val404 in the SARS-CoV-RBD with Lys417 in the SARS-CoV-2-RBD. In addition, from SARS-CoV-RBD to SARS-CoV-2-RBD, the substitution of interface residues Tyr442→Leu455, Leu443→Phe456, Phe460→Tyr473, and Asn479→Gln493 may also change the affinity for ACE2 (Fig. 5C). At the C terminus of α1, Leu472 in the SARS-CoV-RBD is replaced by Phe486 in the SARS-CoV-2-RBD (Fig. 5D).
Fig. 5 Interface comparison between SARS-CoV-2-RBD and SARS-CoV-RBD with ACE2.
(A) Structural alignment for the SARS-CoV-2-RBD and SARS-CoV-RBD. The structure of the ACE2-PD and the SARS-CoV-RBD complex (PDB 2AJF) is superimposed on our cryo-EM structure of the ternary complex relative to the RBDs. The regions enclosed by the purple, blue, and red dashed lines are illustrated in detail in (B) to (D), respectively. SARS-CoV-2-RBD and the PD in our cryo-EM structure are colored orange and cyan, respectively; SARS-CoV-RBD and its complexed PD are colored green and gold, respectively. (B to D) Variation of the interface residues between SARS-CoV-2-RBD (labeled in brown) and SARS-CoV-RBD (labeled in green).
Discussion
Although ACE2 is a chaperone for B0AT1, our focus is on ACE2 in this study. With the stabilization by B0AT1, we elucidated the structure of full-length ACE2. B0AT1 is not involved in dimerization, suggesting that ACE2 may be a homodimer even in the absence of B0AT1. Further examination suggests that a dimeric ACE2 can accommodate two S protein trimers, each through a monomer of ACE2 (fig. S9). The trimeric structure of the S protein of SARS-CoV-2 was recently reported, with one RBD in an up conformation and two in down conformations (PDB 6VSB) (14). The PD clashes with the rest of the S protein when the ternary complex is aligned to the RBD of the down conformation. There is no clash when the complex is superimposed on RDB in the up conformation, with a RMSD of 0.98 Å over 126 pairs of Cα atoms, confirming that an up conformation of RDB is required to bind to the receptor (fig. S9) (14).
Cleavage of the S protein of SARS-CoV is facilitated by cathepsin L in endosomes, indicating a mechanism of receptor-mediated endocytosis (10). Further characterization is required to examine the interactions between ACE2 and the viral particle as well as the effect of cofactors on this process (25, 33). It remains to be investigated whether there is clustering between the dimeric ACE2 and trimeric S proteins, which may be important for invagination of the membrane and endocytosis of the viral particle, a process similar to other types of receptor-mediated endocytosis.
Cleavage of the C-terminal segment, especially residues 697 to 716 (fig. S4), of ACE2 by proteases, such as transmembrane protease serine 2 (TMPRSS2), enhances the S protein–driven viral entry (34, 35). Residues 697 to 716 form the third and fourth helices in the neck domain and map to the dimeric interface of ACE2. The presence of B0AT1 may block the access of TMPRSS2 to the cutting site on ACE2. The expression distribution of ACE2 is broader than that of B0AT1. In addition to kidneys and intestine, where B0AT1 is mainly expressed, ACE2 is also expressed in lungs and heart (27). It remains to be tested whether B0AT1 can suppress SARS-CoV-2 infection by blocking ACE2 cleavage. Enteric infections have been reported for SARS-CoV, and possibly also for SARS-CoV-2 (36, 37). B0AT1 has also been shown to interact with another coronavirus receptor, aminopeptidase N (APN or CD13) (38). These findings suggest that B0AT1 may play a regulatory role for the enteric infections of some coronaviruses.
Comparing the interaction interfaces of SARS-CoV-2-RBD and SARS-CoV-RBD with ACE2 reveals some variations that may strengthen the interactions between SARS-CoV-2-RBD and ACE2 and other variations that are likely to reduce the affinity compared with SARS-CoV-RBD and ACE2. For instance, the change from Val404 to Lys317 may result in a tighter association because of the salt bridge formation between Lys317 and Asp30 of ACE2 (Figs. 4C and 5C). The change from Leu472 to Phe486 may also result in a stronger van der Waals contact with Met82 (Fig. 5D). However, replacement of Arg426 with Asn439 appears to weaken the interaction by eliminating one important salt bridge with Asp329 on ACE2 (Fig. 5B).
Our structural work reveals the high-resolution structure of full-length ACE2 in a dimeric assembly. Docking the S protein trimer onto the structure of the ACE2 dimer with the RBD of the S protein bound suggests simultaneous binding of two S protein trimers to an ACE2 dimer. Structure-based rational design of binders with enhanced affinities to either ACE2 or the S protein of the coronaviruses may facilitate development of decoy ligands or neutralizing antibodies for suppression of viral infection.
Acknowledgments
We thank the Cryo-EM Facility and Supercomputer Center of Westlake University for providing cryo-EM and computation support, respectively. This work was funded by the National Natural Science Foundation of China (projects 31971123, 81920108015, and 31930059), the Key R&D Program of Zhejiang Province (2020C04001), and the SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province (2020C03129). Author contributions: Q.Z. and R.Y. conceived the project. Q.Z. and R.Y. designed the experiments. All authors performed the experiments. Q.Z., R.Y., Y.Z., and Y.L. contributed to data analysis. Q.Z. and R.Y. wrote the manuscript. Competing interests: The authors declare no competing interests. Data and materials availability: Atomic coordinates and cryo EM maps for the ACE2-B0AT1 complex of closed conformation (whole structure and map, PDB 6M18 and EMD-30040; extracellular region map, EMD-30044; and TM region map, EMD-30045), the ACE2-B0AT1 complex of open conformation (PDB 6M1D and EMD-30041), and the complex of the RBD of SARS-CoV-2 with the ACE2-B0AT1 complex (whole structure and map, PDB 6M17 and EMD-30039; extracellular region map, EMD-30042; TM region map, EMD-30043; and ACE2-RBD interface map, EMD-30046) have been deposited in the Protein Data Bank (www.rcsb.org) and the Electron Microscopy Data Bank (www.ebi.ac.uk/pdbe/emdb/). Correspondence and requests for materials should be addressed to corresponding author Q.Z. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.
Supplementary Material
Summary
Materials and Methods
Figs. S1 to S9
Table S1
MDAR Reproducibility Checklist
Movie S1
Resources
File (abb2762_mdar_reproducibility_checklist.pdf)
File (abb2762_yan_sm.pdf)
File (abb2762s1.mp4)
References and notes
1
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan; China Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
2
P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature (2020).
3
T. M. Gallagher, M. J. Buchmeier, Coronavirus spike proteins in viral entry and pathogenesis. Virology 279, 371–374 (2001).
4
G. Simmons, P. Zmora, S. Gierer, A. Heurich, S. Pöhlmann, Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 100, 605–614 (2013).
5
S. Belouzard, V. C. Chu, G. R. Whittaker, Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. U.S.A. 106, 5871–5876 (2009).
6
G. Simmons, J. D. Reeves, A. J. Rennekamp, S. M. Amberg, A. J. Piefer, P. Bates, Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 101, 4240–4245 (2004).
7
W. Song, M. Gui, X. Wang, Y. Xiang, Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLOS Pathog. 14, e1007236 (2018).
8
F. Li, W. Li, M. Farzan, S. C. Harrison, Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864–1868 (2005).
9
J. K. Millet, G. R. Whittaker, Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Res. 202, 120–134 (2015).
10
G. Simmons, D. N. Gosalia, A. J. Rennekamp, J. D. Reeves, S. L. Diamond, P. Bates, Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102, 11876–11881 (2005).
11
M. Hoffmann, H. Kleine-Weber, N. Krüger, M. Müller, C. Drosten, S. Pöhlmann, The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020.01.31.929042 [Preprint]. 31 January 2020. https://doi.org/10.1101/2020.01.31.929042.
12
W. Li, M. J. Moore, N. Vasilieva, J. Sui, S. K. Wong, M. A. Berne, M. Somasundaran, J. L. Sullivan, K. Luzuriaga, T. C. Greenough, H. Choe, M. Farzan, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).
13
K. Kuba, Y. Imai, S. Rao, H. Gao, F. Guo, B. Guan, Y. Huan, P. Yang, Y. Zhang, W. Deng, L. Bao, B. Zhang, G. Liu, Z. Wang, M. Chappell, Y. Liu, D. Zheng, A. Leibbrandt, T. Wada, A. S. Slutsky, D. Liu, C. Qin, C. Jiang, J. M. Penninger, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005).
14
D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science eabb2507 (2020).
15
M. Donoghue, F. Hsieh, E. Baronas, K. Godbout, M. Gosselin, N. Stagliano, M. Donovan, B. Woolf, K. Robison, R. Jeyaseelan, R. E. Breitbart, S. Acton, A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1–E9 (2000).
16
H. Zhang, Z. Kang, H. Gong, J. W. Da Xu, Z. Li, X. Cui, J. Xiao, T. Meng, W. Zhou, J. Liu, H. Xu, The digestive system is a potential route of 2019-nCov infection: A bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020.01.30.927806 [Preprint]. 31 January 2020. https://doi.org/10.1101/2020.01.30.927806.
17
Y. Zhao, Z. Zhao, Y. Wang, Y. Zhou, Y. Ma, W. Zuo, Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020.01.26.919985 [Preprint]. 26 January 2020. https://doi.org/10.1101/2020.01.26.919985.
18
M. A. Crackower, R. Sarao, G. Y. Oudit, C. Yagil, I. Kozieradzki, S. E. Scanga, A. J. Oliveira-dos-Santos, J. da Costa, L. Zhang, Y. Pei, J. Scholey, C. M. Ferrario, A. S. Manoukian, M. C. Chappell, P. H. Backx, Y. Yagil, J. M. Penninger, Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822–828 (2002).
19
L. S. Zisman, R. S. Keller, B. Weaver, Q. Lin, R. Speth, M. R. Bristow, C. C. Canver, Increased angiotensin-(1-7)–forming activity in failing human heart ventricles: Evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108, 1707–1712 (2003).
20
M. K. Raizada, A. J. Ferreira, ACE2: A new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 50, 112–119 (2007).
21
H. Zhang, J. Wada, K. Hida, Y. Tsuchiyama, K. Hiragushi, K. Shikata, H. Wang, S. Lin, Y. S. Kanwar, H. Makino, Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J. Biol. Chem. 276, 17132–17139 (2001).
22
I. Hamming, M. E. Cooper, B. L. Haagmans, N. M. Hooper, R. Korstanje, A. D. M. E. Osterhaus, W. Timens, A. J. Turner, G. Navis, H. van Goor, The emerging role of ACE2 in physiology and disease. J. Pathol. 212, 1–11 (2007).
23
R. N. Kirchdoerfer, N. Wang, J. Pallesen, D. Wrapp, H. L. Turner, C. A. Cottrell, K. S. Corbett, B. S. Graham, J. S. McLellan, A. B. Ward, Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 15701 (2018).
24
P. Towler, B. Staker, S. G. Prasad, S. Menon, J. Tang, T. Parsons, D. Ryan, M. Fisher, D. Williams, N. A. Dales, M. A. Patane, M. W. Pantoliano, ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 279, 17996–18007 (2004).
25
S. Kowalczuk, A. Bröer, N. Tietze, J. M. Vanslambrouck, J. E. J. Rasko, S. Bröer, A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J. 22, 2880–2887 (2008).
26
H. F. Seow, S. Bröer, A. Bröer, C. G. Bailey, S. J. Potter, J. A. Cavanaugh, J. E. J. Rasko, Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat. Genet. 36, 1003–1007 (2004).
27
R. Kleta, E. Romeo, Z. Ristic, T. Ohura, C. Stuart, M. Arcos-Burgos, M. H. Dave, C. A. Wagner, S. R. M. Camargo, S. Inoue, N. Matsuura, A. Helip-Wooley, D. Bockenhauer, R. Warth, I. Bernardini, G. Visser, T. Eggermann, P. Lee, A. Chairoungdua, P. Jutabha, E. Babu, S. Nilwarangkoon, N. Anzai, Y. Kanai, F. Verrey, W. A. Gahl, A. Koizumi, Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat. Genet. 36, 999–1002 (2004).
28
A. Bröer, K. Klingel, S. Kowalczuk, J. E. J. Rasko, J. Cavanaugh, S. Bröer, Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J. Biol. Chem. 279, 24467–24476 (2004).
29
A. Penmatsa, K. H. Wang, E. Gouaux, X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
30
J. A. Coleman, E. M. Green, E. Gouaux, X-ray structures and mechanism of the human serotonin transporter. Nature 532, 334–339 (2016).
31
L. Mastroberardino, B. Spindler, R. Pfeiffer, P. J. Skelly, J. Loffing, C. B. Shoemaker, F. Verrey, Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395, 288–291 (1998).
32
R. Yan, X. Zhao, J. Lei, Q. Zhou, Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature 568, 127–130 (2019).
33
Q. Lin, R. S. Keller, B. Weaver, L. S. Zisman, Interaction of ACE2 and integrin beta1 in failing human heart. Biochim. Biophys. Acta 1689, 175–178 (2004).
34
A. Shulla, T. Heald-Sargent, G. Subramanya, J. Zhao, S. Perlman, T. Gallagher, A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 85, 873–882 (2011).
35
A. Heurich, H. Hofmann-Winkler, S. Gierer, T. Liepold, O. Jahn, S. Pöhlmann, TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 88, 1293–1307 (2014).
36
C. Drosten, S. Günther, W. Preiser, S. van der Werf, H.-R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R. A. M. Fouchier, A. Berger, A.-M. Burguière, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J.-C. Manuguerra, S. Müller, V. Rickerts, M. Stürmer, S. Vieth, H.-D. Klenk, A. D. M. E. Osterhaus, H. Schmitz, H. W. Doerr, Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976 (2003).
37
C. Yeo, S. Kaushal, D. Yeo, Enteric involvement of coronaviruses: Is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol. Hepatol. S2468-1253(20)30048-0 (2020).
38
J. Jando, S. M. R. Camargo, B. Herzog, F. Verrey, Expression and regulation of the neutral amino acid transporter B0AT1 in rat small intestine. PLOS ONE 12, e0184845 (2017).
39
J. Lei, J. Frank, Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscope. J. Struct. Biol. 150, 69–80 (2005).
40
S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
41
T. Grant, N. Grigorieff, Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6. eLife 4, e06980 (2015).
42
K. Zhang, Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).
43
J. Zivanov, T. Nakane, B. O. Forsberg, D. Kimanius, W. J. H. Hagen, E. Lindahl, S. H. W. Scheres, New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
44
D. Kimanius, B. O. Forsberg, S. H. Scheres, E. Lindahl, Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. eLife 5, e18722 (2016).
45
S. H. Scheres, RELION: Implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).
46
S. H. Scheres, A Bayesian view on cryo-EM structure determination. J. Mol. Biol. 415, 406–418 (2012).
47
A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
48
P. B. Rosenthal, R. Henderson, Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J. Mol. Biol. 333, 721–745 (2003).
49
S. Chen, G. McMullan, A. R. Faruqi, G. N. Murshudov, J. M. Short, S. H. W. Scheres, R. Henderson, High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. Ultramicroscopy 135, 24–35 (2013).
50
L. G. Trabuco, E. Villa, K. Mitra, J. Frank, K. Schulten, Flexible fitting of atomic structures into electron microscopy maps using molecular dynamics. Structure 16, 673–683 (2008).
51
P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
52
P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Information & Authors
Information
Published In
Science
Volume 367 | Issue 6485
27 March 2020
27 March 2020
Copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).
This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article versions
You are viewing the most recent version of this article.
Submission history
Received: 12 February 2020
Accepted: 3 March 2020
Published in print: 27 March 2020
Acknowledgments
We thank the Cryo-EM Facility and Supercomputer Center of Westlake University for providing cryo-EM and computation support, respectively. This work was funded by the National Natural Science Foundation of China (projects 31971123, 81920108015, and 31930059), the Key R&D Program of Zhejiang Province (2020C04001), and the SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province (2020C03129). Author contributions: Q.Z. and R.Y. conceived the project. Q.Z. and R.Y. designed the experiments. All authors performed the experiments. Q.Z., R.Y., Y.Z., and Y.L. contributed to data analysis. Q.Z. and R.Y. wrote the manuscript. Competing interests: The authors declare no competing interests. Data and materials availability: Atomic coordinates and cryo EM maps for the ACE2-B0AT1 complex of closed conformation (whole structure and map, PDB 6M18 and EMD-30040; extracellular region map, EMD-30044; and TM region map, EMD-30045), the ACE2-B0AT1 complex of open conformation (PDB 6M1D and EMD-30041), and the complex of the RBD of SARS-CoV-2 with the ACE2-B0AT1 complex (whole structure and map, PDB 6M17 and EMD-30039; extracellular region map, EMD-30042; TM region map, EMD-30043; and ACE2-RBD interface map, EMD-30046) have been deposited in the Protein Data Bank (www.rcsb.org) and the Electron Microscopy Data Bank (www.ebi.ac.uk/pdbe/emdb/). Correspondence and requests for materials should be addressed to corresponding author Q.Z. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.
Authors
Funding Information
National Natural Science Foundation of China: 81920108015
Key R&D Program of Zhejiang Province: 2020C04001
the SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province: 2020C03129
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Modelling the adsorption of proteins to nanoparticles at the solid-liquid interface, Journal of Colloid and Interface Science, 605, (286-295), (2022).https://doi.org/10.1016/j.jcis.2021.07.072
- The role of traditional medicine in the fight against SARS-CoV-2, Biomedical Innovations to Combat COVID-19, (339-385), (2022).https://doi.org/10.1016/B978-0-323-90248-9.00019-X
- A molecular dynamic study on the ability of phosphorene for designing new sensor for SARS-CoV-2 detection, Journal of Molecular Liquids, 345, (117852), (2022).https://doi.org/10.1016/j.molliq.2021.117852
- Defining biological and biophysical properties of SARS-CoV-2 genetic material in wastewater, Science of The Total Environment, 807, (150786), (2022).https://doi.org/10.1016/j.scitotenv.2021.150786
- Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry, Science, 375, 6579, (449-454), (2022)./doi/10.1126/science.abm8143
- Immunological characteristics govern the transition of COVID-19 to endemicity, Science, 371, 6530, (741-745), (2021)./doi/10.1126/science.abe6522
- Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM, Science Advances, 7, 1, (2021)./doi/10.1126/sciadv.abe5575
- Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates, Science Advances, 7, 12, (2021)./doi/10.1126/sciadv.abf1591
- Cytoplasmic short linear motifs in ACE2 and integrin β3 link SARS-CoV-2 host cell receptors to mediators of endocytosis and autophagy, Science Signaling, 14, 665, (2021)./doi/10.1126/scisignal.abf1117
- Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications, Science Signaling, 14, 665, (2021)./doi/10.1126/scisignal.abd0334
- See more
Loading...
View Options
View options
PDF format
Download this article as a PDF file
Download PDFGet Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Register for free to read this article
As a service to the community, this article is available for free. Login or register for free to read this article.
Buy a single issue of Science for just $15 USD.
RE: ACE2 Homodimerization Affects Binding of SARS-CoV-2 Spike Protein
Yan et.al. 2020 proposed the binding of two SARS-CoV-2 Spike Glycoproteins (SGs) with Angiotensin-converting enzyme 2 (ACE2) homodimer without affecting each other or any structural hindrance (1). We appreciate the extensive work done and important findings. However, we believe binding of two SGs to ACE2 homodimer is only possible in modelled version as given, but not naturally. At the same time, the alternate explanation we provide may help find an answer to the question that despite being a receptor for SARS-CoV-2, how can ACE2 still perform its physiological role of protection from severe Lung injury, in some COVID-19 patients (2). Alignment of receptor binding domain (RBD) (6M17.pdb), with the prefusion SARS-CoV-2 SG (6VSB.pdb), in the optimal ACE2 binding conformation (Figure 1') provided in detailed manuscript preprint at https://www.biorxiv.org/content/10.1101/2020.04.24.050534v3 with "up CTD1" and "open S1 subunit" (1, 3)has shown no steric clash with the ACE2 or another SG, as reported (1). We extended the evaluation and noted that both SGs protrude radially outward from ACE2 protease domains (PDs). RBDs are 6 nanometer (nm) apart at PDs and anchorage sites of SGs on virus membrane are approximately at a distance of 27 nm (Figure 1'b). However, considering the reported inter spike distance of 13-15 nm (4) on the viral shell, given almost similar sizes of SARS-CoV (4, 5) and SARS-CoV-2 (6), SGs are anticipated to be either parallel or protruding radially outwards from its anchorage site (Figure 1'b), contrasting to the findings in modelled structure (1). Thus, we propose that structural hinderances caused by ACE2 homodimerization, induced by factors like over expression (7), may result in binding of only one SG to dimerized ACE2. The other unbound ACE2 partner might remain free, for its physiological role and continue to protect from lung injury.
References
1. R. Yan et al., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444-1448 (2020).
The authors declare no competing interests associated with MS. For declaration purposes, SS is founder, chief scientific advisor of a startup "Biodroid Innovations Pvt Ltd" and IP is director of "Bioinfores Pvt. Ltd.""2. M. Vaduganathan et al., Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 382, 1653-1659 (2020).
3. D. Wrapp et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263 (2020).
4. B. W. Neuman et al., Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy. Journal of virology 80, 7918-7928 (2006).
5. C. S. Goldsmith et al., Ultrastructural characterization of SARS coronavirus. Emerg Infect Dis 10, 320-326 (2004).
6. N. Chen et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507-513 (2020).
7. S. Sharma et al., ACE2 Homo-dimerization, Human Genomic variants and Interaction of Host Proteins Explain High Population Specific Differences in Outcomes of COVID19. bioRxiv, 2020.2004.2024.050534 (2020).
RE: Molecular mechanism of SARS-CoV-2-RBD and human ACE2 from their 3D structures
Computational studies of human-virus protein-protein interactions from their 3D structures have been playing important roles to discover successful drugs for various viruses such as HIV-1, hepatitis C virus, and norovirus (1). The spike receptor-binding domain of SARS-CoV-2 (SARS-CoV-2-RBD) binds to human angiotensin-converting enzyme 2 (ACE2) to initiate entry into human cells (2), which is currently a crucial target for anti-viral therapeutics.
Since Science has recently published two papers for cryo-EM structures of SARS-CoV-2 spike protein (PDB code: 6VSB, resolution: 3.46Å) (3), SARS-CoV-2-RBD and human ACE2 (PDB code: 6M17, resolution: 2.90Å) (4), and Protein Data Bank released a new crystal structures of SARS-CoV-2-RBD and human ACE2 on 18 March 2020 (PDB code: 6LZG, resolution: 2.50Å) (5), and Nature just published a new paper for another crystal structures of SARS-CoV-2-RBD and human ACE2 on 30 March 2020 (PDB code: 6M0J, resolution: 2.45Å) (6), we can start to ask questions about (i) how these structures could help us understand the underlying principles and molecular mechanisms of interactions between SARS-CoV-2-RBD and ACE2, and (ii) which structure we should select for further study to facilitate the development of therapeutics.
In order to answer these questions, we have used our programs (7) for dissecting the contributions of hydrogen bonds (Hbond), hydrophobic interactions, van der Waals interactions (vdW), ionic interactions, and interfacial water molecules at the interfaces of SARS-CoV-2-RBD with ACE2 from three structures 6M17, 6LZG, 6M0J and SARS-CoV-RBD with ACE2 from 2AJF (8). Surprisingly, the number of interactions at the interface of SARS-CoV-2-RBD and ACE2 from 6M17 (4 Hbonds, 42 hydrophobic, 53 vdW, 2 ionic interactions) are much smaller than those of SARS-CoV-RBD and ACE2 (7 Hbonds, 67 hydrophobic, 90 vdW, 4 ionic interactions, 1 Hbond with interfacial waters). The analyses from 6M17 do not agree with the binding experiments that have demonstrated that the affinity SARS-CoV-2-RBD for ACE2 is higher than that of SARS-CoV-RBD for ACE2 (3, 9). Meanwhile, the number of interactions at the interface of SARS-CoV-2-RBD and ACE2 from the structure 6M0J (10 Hbonds, 76 hydrophobic, 99 vdW, 3 ionic interactions) and 6LZG (12 Hbonds, 80 hydrophobic, 107 vdW, 3 ionic interactions, 9 Hbonds with interfacial waters) agree well with the binding experiments. Notably, in our analyses only structure 6LZG could show Hbonds of the critical residues Gln493 and Asn501 of SARS-CoV-2-RBD (10) with Glu35 and Tyr41 of ACE2.
Comparing 3D structures of interfaces between ACE2 with SARS-CoV-2-RBD and SARS-CoV-RBD using our CLICK method (11, 12) reveals new interactions that are recently not reported in the study of 6M17 (4). The interfaces of SARS-CoV-2-RBD of the structures 6LZG and 6M0J have eight residues Tyr449, Tyr453, Asn487, Tyr489, Gly496, Thr500, Gly502, Tyr505 that are not only conserved but also occupy identical spacial locations with Tyr436, Tyr440, Asn473, Tyr475, Gly482, Thr486, Gly488, Tyr491 of SARS-CoV-RBD from 2AJF. Especially, our analyses for 6LZG and 6M0J indicate that these eight conserved binding residues with four conserved Tyr of SARS-CoV-2-RBD have 8 Hbonds with ACE2 and interfacial waters that significantly support for convergent evolution between SARS-CoV-2-RBD and SARS-CoV-RBD for binding ACE2 as the conserved binding residues of SARS-CoV-RBD have 6 Hbonds with ACE2. Meanwhile, the conserved binding residues of SARS-CoV-2-RBD from the structure 6M17 has only 4 Hbonds with ACE2. The detailed analyses of our study are available at: http://mspc.bii.a-star.edu.sg/minhn/covid19.html
Our analyses have indicated that the structure 6LZG could identify more significant interactions as well as interfacial water molecules at the interfaces of SARS-CoV-2-RBD with ACE2 compared to 6M17 (4) and 6M0J (6). Since Science recently published the study of structure 6M17 in March 2020, we believe that many groups have been using or could have a plan to use this structure for their studies that may affect their final results because some important interactions at the interfaces of SARS-CoV-2-RBD and ACE2 are not captured in this structure.
References and Notes
1. K-O. Chang et al., Viruses 11, 197, (2019). doi: 10.3390/v11020197
2. P. Zhou et al., Nature 579, (2020). doi:10.1038/s41586-020-2012-7
3. D. Wrapp et al., Science (2020). doi: 10.1126/science.abb2507
4. R. Yan et al., Science (2020). doi: 10.1126/science.abb2762
5. http://www.rcsb.org/structure/6LZG
6. J. Lan et al., Nature (2020). doi:10.1038/s41586-020-2180-5
7. M. N. Nguyen et al., Nucleic Acids Res. 47, (2019). doi:10.1093/nar/gkz358
8. F. Li et al., Science 309, (2005). doi:10.1126/science.1116480
9. W. Tai et al., Cell Mol Immunol (2020). doi:10.1038/s41423-020-0400-4
10. Y. Wan et al., J. Virol. (2020). doi:10.1128/JVI.00127-20
11. M. N. Nguyen, M. S. Madhusudhan, Nucleic Acids Res. 39, 14, (2011) doi:10.1093/nar/gkr348
12. M. N. Nguyen et al., Bioinformatics 33, 19, (2017). doi:10.1093/bioinformatics/btx389
Competing Interests
This research is supported by the Agency for Science, Technology and Research (A*STAR) under its Industry Alignment Fund – Pre-Positioning Programme (IAF-PP) grant number H18/01/a0/B14 as part of the A*STAR Innovations in Food and Chemical Safety (IFCS) Programme. C.S.V. is the founder/scientific consultant of Sinopsee Therapeutics, a biotechnology company developing molecules for therapeutic purposes; the current work has no conflict with the company.
RE: ACE-inhibitors and Angiotensin II receptor blockers: are they dangerous in case of SARS-CoV-2-infection?
Your Science paper (1) reported the structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. This confirms that the novel virus SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) as a receptor similar to SARS-CoV. Zhou et al demonstrated that ACE2 overexpressing in vitro can allow SARS-CoV-2 infection and replication, mediating CoV spike protein's interaction with the ACE2 (2). These findings provide important insights into the molecular basis of the angiotensin/renin system for coronavirus recognition and infection.
In clinical practice, Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARB) are extensively used for the treatment of various cardiovascular diseases, like hypertension, ischemic or idiopathic heart disease, and diabetic nephropathy.
It has been underlined that in a rat model, the cardiac ACE2 mRNA expression, after treatment with the ACE-inhibitor lisinopril, increased in comparison to the controls, and also after treatment with the angiotensin II (AT)1 receptor blocker losartan (3).
Among the clinicians, the fear has been therefore raising that the ACE-2 overexpression after treatment with the two classes of drugs (4) could favor the viral lung tissue colonization in SARS-CoV-2-infected patients.
In the opposite direction, it has recently been suggested that the ARB could potentially be useful in clinical course of COVID-19 patients (5).
The above cited, at times contradictory, evidence suggests that previous treatment with ACE inhibitors and AR Blockers could have different effects on clinical course of hypertension patients affected by SARS-CoV-2, many of which are assuming one of the other class of drugs.
Due to substantial numbers of hypertensive, diabetic and cardio-vascular patients in the world currently treated with ace-inhibitors or ARB, we propose a survey employed in a prospective, international study on the patients affected by SARS-CoV-2 virus infection, with the purpose to evaluating the effects on clinical course of the two class of drugs. This study is urgent to develop guidelines of hypertension treatment in the SARS-CoV-2 era.
References
1. R. Yan et al., Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science, (2020).
2. P. Zhou et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273 (2020).
3. C. M. Ferrario et al., Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605-2610 (2005).
4. L. Fang, G. Karakiulakis, M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, (2020).
5. D. Gurwitz, Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, (2020).
6. S. Q. Deng, H. J. Peng, Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med 9, (2020).
7. B. Li et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol, (2020).
8. J. Yang et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, (2020).